XenoPort has received a US patent for, prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use.
The patent is directed to composition and formulations of the XP23829 compound and another patent application directed to therapeutic uses of XP23829 is now pending, the company said.
XP23829 is a prodrug of methyl hydrogen fumarate, also known as monomethyl fumarate (MMF).
The term of the patent extends until 2029 and is subject to potential Hatch-Waxman patent term extensions.
The company aims to file an investigational new drug application for XP23829 for the treatment of relapsing remitting MS with the FDA in the second quarter of 2012 and look forward to initiate human clinical trials later this year.
